Aymen A. Bash
Research Subjects
Aymen A. Bash has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Esaim Fadhel Khalfa1 shared publication
- Fatima Adnan Alzubaidi
Department of Pharmacology and Toxicology, College of Pharmacy, University of Babylon, Babylon, Iraq
1 shared publication - Ghassan Jasim Mohammed
Faculty of Pharmacy, University of Babylon, Babylon,51002, Iraq
1 shared publication - Hussam Al-Humadi
Department of Pharmacology, Medical School, National and Kapodistrian University of Athens, Athens, Greece
1 shared publication - Ismael Obaidi
Cell Technology Group, National Institute for Bioprocessing, Research and Training (NIBRT), Fosters Avenue, Mount Merrion, Blackrock, Dublin A94 X099, Ireland; Cell Technology Group, National Institute for Bioprocessing, Research and Training (NIBRT), Fosters Avenue, Mount Merrion, Blackrock, Dublin A94 X099, Ireland; School of Pharmacy, University of Babylon, Babylon, Iraq
1 shared publication - Junying Liu
NatPro Center, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, D02 PN40 Dublin, Ireland
1 shared publication
Latest Publications
- 5 May 2024
- Published by PHARMAKON-PRESS in Review of Clinical Pharmacology and Pharmacokinetics - International Edition
- Vol. 38 (Sup2) , 133-136
Drug synthesis, separation, and identification of a di-stereoisomeric mixture of spiro-oxalidinonic derivatives of sorbinil by high-performance liquid chromatography
A straightforward and sensitive method for high-performance liquid chromatography (HPLC) was created in order to separate and identify the di-stereoisomeric mixture of a spiro-oxalidinonic derivative of sorbinil. HPLC was carried out using a C18 reversed-phase column. The mobile phase used in the isocratic elution process was a 70:30 v/v combi¬nation of methanol and acetonitrile flowed at a rate of 2 mL/min. The procedure delivered the best result among the various attempts made. Two peaks were identified on the chromatogram, attributable to the two di-stereoisomers of the mixture analysed. Analogues of sorbinil, a powerful inhibitor of aldose reductase, have been synthesized and further tested on aldose reductase as mixtures of di-stereoisomers, exhibiting an IC50 in the order of the micromolar. The structure of the compounds was checked with nuclear magnetic resonance spectroscopy. The chemical shifts were expressed in ppm scale δ.
- 5 May 2024
- Published by PHARMAKON-PRESS in Review of Clinical Pharmacology and Pharmacokinetics - International Edition
- Vol. 38 (Sup2) , 133-136
Drug synthesis, separation, and identification of a di-stereoisomeric mixture of spiro-oxalidinonic derivatives of sorbinil by high-performance liquid chromatography
A straightforward and sensitive method for high-performance liquid chromatography (HPLC) was created in order to separate and identify the di-stereoisomeric mixture of a spiro-oxalidinonic derivative of sorbinil. HPLC was carried out using a C18 reversed-phase column. The mobile phase used in the isocratic elution process was a 70:30 v/v combi¬nation of methanol and acetonitrile flowed at a rate of 2 mL/min. The procedure delivered the best result among the various attempts made. Two peaks were identified on the chromatogram, attributable to the two di-stereoisomers of the mixture analysed. Analogues of sorbinil, a powerful inhibitor of aldose reductase, have been synthesized and further tested on aldose reductase as mixtures of di-stereoisomers, exhibiting an IC50 in the order of the micromolar. The structure of the compounds was checked with nuclear magnetic resonance spectroscopy. The chemical shifts were expressed in ppm scale δ.
- 5 May 2024
- Published by PHARMAKON-PRESS in Review of Clinical Pharmacology and Pharmacokinetics - International Edition
- Vol. 38 (Sup2) , 157-160
Novel anticancer mechanisms of JinYingZi-derived oleanolic acid against renal cell carcinoma: an in silico analysis
Renal cell carcinoma (RCC) is the most common type of kidney cancer, accounting for 90% of all estimated cases. Advanced RCC often carries poor prognosis due to its high metastases rate, the lack of early-warning signs, as well as its complex clinical manifestations and its resistance to chemotherapy. Ethnopharmacologically, Fructus Rosae laevigata (JinYingZi) has been employed by Chinese medicine to treat various urinary tract and gastrointestinal dis¬orders. This study aimed at performing a series of mechanistic analyses in order to unlock the anticancer potential of JinYingZi-derived bioactive components against RCC. Several network pharmacology tools were employed so as to analyse the drug-disease interactions. Our data revealed that more than 2,214 genes were dysregulated in RCC, whereas the JinYingZi-derived bioactive compounds modulated 347 genes. The intersecting between RCC and the bioactive compounds revealed 132 cross targets. Our results were further validated by conducting molecular docking, which revealed a stable association between oleanolic acid with each of the following targets: androgen receptor (AR), dipeptidyl peptidase (DPP), estradiol (ESR1), nitric oxide synthase 2 (NOS2), and cyclooxygenase-2 (PTGS2). Our approach is being used successfully in order to evaluate a panel of novel medicinal plant-derived bioactive com¬pounds, and may lead to the identification of safe and effective chemical scaffolds that could act as templates for drug discovery or yield potential drug candidates.
- 5 May 2024
- Published by PHARMAKON-PRESS in Review of Clinical Pharmacology and Pharmacokinetics - International Edition
- Vol. 38 (Sup2) , 157-160
Novel anticancer mechanisms of JinYingZi-derived oleanolic acid against renal cell carcinoma: an in silico analysis
Renal cell carcinoma (RCC) is the most common type of kidney cancer, accounting for 90% of all estimated cases. Advanced RCC often carries poor prognosis due to its high metastases rate, the lack of early-warning signs, as well as its complex clinical manifestations and its resistance to chemotherapy. Ethnopharmacologically, Fructus Rosae laevigata (JinYingZi) has been employed by Chinese medicine to treat various urinary tract and gastrointestinal dis¬orders. This study aimed at performing a series of mechanistic analyses in order to unlock the anticancer potential of JinYingZi-derived bioactive components against RCC. Several network pharmacology tools were employed so as to analyse the drug-disease interactions. Our data revealed that more than 2,214 genes were dysregulated in RCC, whereas the JinYingZi-derived bioactive compounds modulated 347 genes. The intersecting between RCC and the bioactive compounds revealed 132 cross targets. Our results were further validated by conducting molecular docking, which revealed a stable association between oleanolic acid with each of the following targets: androgen receptor (AR), dipeptidyl peptidase (DPP), estradiol (ESR1), nitric oxide synthase 2 (NOS2), and cyclooxygenase-2 (PTGS2). Our approach is being used successfully in order to evaluate a panel of novel medicinal plant-derived bioactive com¬pounds, and may lead to the identification of safe and effective chemical scaffolds that could act as templates for drug discovery or yield potential drug candidates.